Last update Jan. 29, 2025
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Azelastine Hydrochloride in other languages or writings:
Azelastine Hydrochloride belongs to these groups or families:
Main tradenames from several countries containing Azelastine Hydrochloride in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | oral: 80. Intranasal 40 | % |
Molecular weight | 418 | daltons |
Protein Binding | 88 - 97 | % |
VD | 14.5 | l/Kg |
pKa | 9.5 | - |
Tmax | 2 - 3 | hours |
T½ | 22 (metabolit: 54) | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Second generation antihistamine with minimal sedative effect. Indicated for allergic and vasomotor rhinitis and allergic conjunctivitis. Oral, nasal and ophthalmic administration.
At the time of last update, no published data on breastfeeding were available.
Pharmacokinetic data (large volume of distribution, moderately high molecular weight and high percentage of plasma protein binding) make passage into breast milk unlikely in clinically significant quantities.
It is a very bitter product that could, if excreted into breast milk, alter its taste and cause rejection by the infant. (Hale).
The small dose and low plasma absorption of most topical nasal or ophthalmologic preparations make passage of significant amounts into breast milk unlikely, so they are considered safe during breastfeeding.
For oral administration, until further published data on this drug in relation to breastfeeding is known, safer alternatives may be preferable, especially during the neonatal period and in case of prematurity. (LactMed, So 2010).